Home>Topics>Stocks>Celgene Corporation

Celgene Corporation CELG

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Wed, 16 Apr 2014

      the broader market over the past five years. The firms at the top of this ETF, such as Regeneron REGN, Biogen BIIB, Celgene CELG , Gilead GILD, and Amgen AMGN, have led the rally, benefiting from key drug approvals, strong sales of already-approved

    2. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Wed, 16 Apr 2014

      outperformed the broader market over the past five years. Some firms held in this ETF, such as Regeneron REGN, Biogen BIIB, Celgene CELG , Gilead GILD, and Amgen AMGN, have led the rally, benefiting from key drug approvals, strong sales of already-approved

    3. FBT First Trust NYSE Arca Biotech Index ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Wed, 16 Apr 2014

      outperformed the broader market over the past five years. Some firms held in this ETF, such as Regeneron REGN, Biogen BIIB, Celgene CELG , Gilead GILD, and Amgen AMGN, have led the rally, benefiting from key drug approvals, strong sales of already-approved

    4. Gilead: This Baby Has Been Thrown Away With The Bathwater

      Headlines

      Wed, 16 Apr 2014

      By Fear & Greed Trader : The Biotech sector has been under severe pressure lately and it seems to make the "headlines" daily as the cause for so much of the NASDAQ weakness. Yes the index ( IBB ) has skyrocketed after a breakout in Nov 2013 tacking on a 30% gain in a mere 3 month time frame . These

    5. Celgene Growth Unappreciated In Recent Sell-Off

      Headlines

      Mon, 14 Apr 2014

      By Purple Chips : Celgene Corporation ( CELG ) is a top biopharmaceutical company currently involved in researching ..... level represents an attractive entry point for a position in CELG . Sharp Increase In Revenues Expected 2014 holds great promise

    6. Today's Market: Playing The Biotech Bloodbath

      Headlines

      Fri, 11 Apr 2014

      By Matthew Smith : There are a few things we have learned in our nearly two decades of investing; first bull markets never turn bearish on a dime and second the best buying opportunities during these bull markets are during the periods when confidence suddenly disappears for seemingly no reason ...

    7. 3 Biotech Companies That Look To Be Good Buys After A Pullback

      Headlines

      Fri, 11 Apr 2014

      By Glen S. Woods: In the past month both Gilead Sciences ( GILD ) and Celgene ( CELG ) stock have has given back over 18% of its value. Amgen ( AMGN ) has fared better only paring back 9% of its value. While

    8. Celgene In Mylan's Cross-Hairs: "I'm Shakin' In My Boots"... Well, Maybe A Little

      Headlines

      Mon, 7 Apr 2014

      By Clayton Rulli: I recently covered the basics of Celgene ( CELG ) in a past article , in which I shared my opinion of how shares are undervalued given growth prospects, upcoming catalysts

    9. AbbVie - Strong Product Pipeline Is Defining Its Future

      Headlines

      Sun, 6 Apr 2014

      By Alpha Strategist : AbbVie Inc. ( ABBV ) is a research based pharmaceutical organization that markets products to more than 170 countries with 57% of the top line attributable to the US alone. The company operates in a single business segment, the pharmaceutical products, with a number of ...

    10. Mylan sues Celegene for blocking generic version of Revlimid, Thalomid

      Headlines

      Fri, 4 Apr 2014

      Mylan ( MYL ) has sued Celgene ( CELG ) over the what Mylan says are illegal actions that Celgene has taken to keep generic versions of its Revlimid and Thalomid blockbuster

    « Prev12345Next »
    Content Partners